Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489785 | 0.93 | CYP17A1 (0.34) | CYP17A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31489626 | 0.91 | JAK2 (0.34) | CYP17A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31489585 | 0.90 | PIK3CD (0.35) | CYP17A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31489761 | 0.86 | JAK2 (0.33) | CYP17A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31489461 | 0.85 | PIK3CD (0.32) | JAK2PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31489532 | 0.84 | JAK2 (0.34) | CYP17A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31489231 | 0.82 | CYP17A1 (0.34) | CYP17A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31489517 | 0.82 | PIK3CD (0.34) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31489337 | 0.81 | JAK2 (0.32) | CYP17A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31489881 | 0.81 | PIK3CD (0.37) | CYP17A1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |